Back to top
more

OXIGENE INC (OXGN)

(Delayed Data from NSDQ)

$0.70 USD

0.70
169,586

-0.03 (-3.69%)

Updated Jun 17, 2016 03:59 PM ET

After-Market: $0.72 (%) 3:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Oncotelic Therapeutics, Inc. [OXGN]

Reports for Purchase

Showing records 1 - 13 ( 13 total )

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/29/2016

Company Report

Pages: 7

Squarely FOCUSed on Initiating Phase 2/3 Trial by Mid-Year; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/12/2015

Company Report

Pages: 8

3Q15 Update: Updated Clinical Strategy Pairs Vascular Disruptors with SOC

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

10/21/2015

Daily Note

Pages: 3

CA4P Shows Early Signs of Activity in Neuroendocrine Tumors

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 10.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

10/01/2015

Company Report

Pages: 7

Management Sets Lofty Goal to Top the Standard of Care in Refractory Ovarian Cancer; Revising PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/05/2015

Company Report

Pages: 10

2Q15 Update - Multifaceted Attack on Tumor Vasculature for Planned Pivotal Ovarian Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

06/04/2015

Daily Note

Pages: 3

Pivotal Guidance Delivered-FDA Gives Thumbs Up for Ovarian Trial Design

Provider: H.C. WAINWRIGHT & CO., INC.

Price: 10.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

05/01/2015

Company Report

Pages: 11

1Q15 Update-Key FDA Guidance Expected in June

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

04/24/2015

Industry Report

Pages: 12

2015 AACR Meeting Highlights-Cancer Gets a Dose of Brotherly Love

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

04/02/2015

Company Report

Pages: 12

4Q14 Update-Pivotal Trial in Ovarian Cancer Could Start by Year?s End

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

02/12/2015

Daily Note

Pages: 3

Cracking Platinum Resistance with the Right Combination of Drugs

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

11/13/2014

Company Report

Pages: 11

3Q14 Update-ZYBRESTAT Hits PFS in Resistant Ovarian Cancer

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

11/11/2014

Daily Note

Pages: 3

We are reiterating our Buy rating and a 12-month target price of $6

Provider: H.C. WAINWRIGHT & CO., INC.

Price: 10.00

Research Provided by a Third Party

Company: Oncotelic Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

07/19/2011

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for OXGN

Provider: VALUENGINE, INC

Price: 25.00

Research Provided by a Third Party
// eof